Arcturus Therapeutics (ARCT) Receives Daily News Impact Score of 0.02

Headlines about Arcturus Therapeutics (NASDAQ:ARCT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Arcturus Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 50.9680553724484 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the stock’s share price in the near future.

Shares of Arcturus Therapeutics (ARCT) traded up $0.01 during trading hours on Friday, hitting $9.07. The company had a trading volume of 17,150 shares, compared to its average volume of 58,336. The firm has a market cap of $95.75, a P/E ratio of -2.27 and a beta of 1.55. Arcturus Therapeutics has a 1 year low of $5.81 and a 1 year high of $15.47.

A number of analysts have issued reports on the company. Zacks Investment Research downgraded Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Roth Capital downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. WBB Securities raised Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Monday, October 9th. Finally, Ladenburg Thalmann Financial Services assumed coverage on Arcturus Therapeutics in a research note on Wednesday, November 29th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $1.50.

WARNING: “Arcturus Therapeutics (ARCT) Receives Daily News Impact Score of 0.02” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thestockobserver.com/2018/01/13/arcturus-therapeutics-arct-receives-daily-news-impact-score-of-0-02.html.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.

Insider Buying and Selling by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply